カテゴリー：世界, 医療/バイオ, Transparency Market Research

世界のエクソソーム技術市場2023-2031：エクソソーム種類別（ロードカーゴ（ペプチド、siRNA、mRNA、miRNA、タンパク質、化学物質、その他）、ノンカーゴ）

【英語タイトル】Exosome Technologies Market (Exosome Type: Loaded Cargos [Peptide, siRNA, mRNA, miRNA, Protein, Chemical, and Others] and Non-cargo) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
	・商品コード：TMR23JUL201 ・発行会社（調査会社）：Transparency Market Research ・発行日：2023年4月・ページ数：208 ・レポート言語：英語・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内）・調査対象地域：北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ・産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥880,840	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,336,840	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,792,840	見積依頼/購入/質問フォーム

※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）

❖ レポートの概要 ❖

Transparency Market Research社の市場調査では、世界のエクソソーム技術市場規模が2023年の47.3百万ドルから2031年には343.5百万ドルに達し、予想期間中の年平均成長率は24.8％を記録すると予想されています。本書では、エクソソーム技術の世界市場ついて広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、エクソソーム種類別（ロードカーゴ、ノンカーゴ）分析、細胞源別（HEK293細胞、間葉系幹細胞、血小板、赤血球、その他）分析、用途別（治療薬、診断薬）分析、エンドユーザー別（医療提供者、製薬・バイオテクノロジー企業、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを整理しました。また、本書には、AEGLE Therapeutics、Aruna Bio, Inc.、Bio-Techne Corporation、Carmine Therapeutics, Inc.、Codiak BioSciences, Inc.、Creative Biolabs、Danaher Corporation (Beckman Coulter, Inc.)、Fujifilm Holdings Corporationなどの企業情報が記載されています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要洞察
・世界のエクソソーム技術市場規模：エクソソーム種類別
- ロードカーゴエクソソーム技術の市場規模
- ノンカーゴエクソソーム技術の市場規模
・世界のエクソソーム技術市場規模：細胞源別
- HEK293細胞における市場規模
- 間葉系幹細胞における市場規模
- 血小板における市場規模
- 赤血球における市場規模
- その他細胞源における市場規模
・世界のエクソソーム技術市場規模：用途別
- 治療薬における市場規模
- 診断薬における市場規模
・世界のエクソソーム技術市場規模：エンドユーザー別
- 医療提供者における市場規模
- 製薬・バイオテクノロジー企業における市場規模
- その他エンドユーザーにおける市場規模
・世界のエクソソーム技術市場規模：地域別
- 北米のエクソソーム技術市場規模
- ヨーロッパのエクソソーム技術市場規模
- アジア太平洋のエクソソーム技術市場規模
- 中南米のエクソソーム技術市場規模
- 中東・アフリカのエクソソーム技術市場規模
・競争状況

Exosome Technologies Market – Scope of Report
TMR’s report on the global Exosome Technologies Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Exosome Technologies Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Exosome Technologies Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Plasmonic Materials market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Plasmonic Materials market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Plasmonic Materials market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Plasmonic Materials market.

The report delves into the competitive landscape of the global Plasmonic Materials market. Key players operating in the global Exosome Technologies Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Exosome Technologies Market profiled in this report.

Key Questions Answered in Global Exosome Technologies Market Report
• What is the sales/revenue generated by Plasmonic Materials across all regions during the forecast period?
• What are the opportunities in the global Plasmonic Materials market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Exosome Technologies Market – Research Objectives and Research Approach
The comprehensive report on the global Exosome Technologies Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Exosome Technologies Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Plasmonic Materials market.
”

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Exosome Technologies Market
4. Market Overview
4.1. Introduction
4.1.1. Exosome Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Exosome Technologies Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
5. Key Insights
5.1. Pipeline Analysis
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Exosome Technologies Market Analysis and Forecasts, by Exosome Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Exosome Type, 2017 – 2031
6.3.1. Loaded Cargos
6.3.1.1. Peptide
6.3.1.2. siRNA
6.3.1.3. mRNA
6.3.1.4. miRNA
6.3.1.5. Protein
6.3.1.6. Chemical
6.3.1.7. Others
6.3.2. Non-cargo
6.4. Market Attractiveness By Exosome Type
7. Global Exosome Technologies Market Analysis and Forecasts, by Cell Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Cell Source, 2017 – 2031
7.3.1. HEK293 Cells
7.3.2. MSCs
7.3.3. Platelets
7.3.4. Erythrocytes
7.3.5. Natural Killer Cells
7.3.6. Others
7.4. Market Attractiveness By Cell Source
8. Global Exosome Technologies Market Analysis and Forecasts, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2017 – 2031
8.3.1. Therapeutics
8.3.1.1. Oncology
8.3.1.2. Neurodegenerative Diseases
8.3.1.3. Cardiovascular Diseases
8.3.1.4. Infectious Diseases
8.3.1.5. Cosmetics
8.3.2. Diagnostics
8.4. Market Attractiveness By Application
9. Global Exosome Technologies Market Analysis and Forecasts, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2017 – 2031
9.3.1. Health Care Providers
9.3.2. Pharmaceutical & Biotechnology Companies
9.3.3. Others
9.4. Market Attractiveness By End-user
10. Global Exosome Technologies Market Analysis and Forecasts, by Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Exosome Technologies Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Exosome Type, 2017 – 2031
11.2.1. Loaded Cargos
11.2.1.1. Peptide
11.2.1.2. siRNA
11.2.1.3. mRNA
11.2.1.4. miRNA
11.2.1.5. Protein
11.2.1.6. Chemical
11.2.1.7. Others
11.2.2. Non-cargo
11.3. Market Value Forecast By Cell Source, 2017 – 2031
11.3.1. HEK293 Cells
11.3.2. MSCs
11.3.3. Platelets
11.3.4. Erythrocytes
11.3.5. Natural Killer Cells
11.3.6. Others
11.4. Market Value Forecast By Application, 2017 – 2031
11.4.1. Therapeutics
11.4.1.1. Oncology
11.4.1.2. Neurodegenerative Diseases
11.4.1.3. Cardiovascular Diseases
11.4.1.4. Infectious Diseases
11.4.1.5. Cosmetics
11.4.2. Diagnostics
11.5. Market Value Forecast By End-user, 2017 – 2031
11.5.1. Health Care Providers
11.5.2. Pharmaceutical & Biotechnology Companies
11.5.3. Others
11.6. Market Value Forecast By Country, 2017 – 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Exosome Type
11.7.2. By Cell Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Exosome Technologies Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Exosome Type, 2017 – 2031
12.2.1. Loaded Cargos
12.2.1.1. Peptide
12.2.1.2. siRNA
12.2.1.3. mRNA
12.2.1.4. miRNA
12.2.1.5. Protein
12.2.1.6. Chemical
12.2.1.7. Others
12.2.2. Non-cargo
12.3. Market Value Forecast By Cell Source, 2017 – 2031
12.3.1. HEK293 Cells
12.3.2. MSCs
12.3.3. Platelets
12.3.4. Erythrocytes
12.3.5. Natural Killer Cells
12.3.6. Others
12.4. Market Value Forecast By Application, 2017 – 2031
12.4.1. Therapeutics
12.4.1.1. Oncology
12.4.1.2. Neurodegenerative Diseases
12.4.1.3. Cardiovascular Diseases
12.4.1.4. Infectious Diseases
12.4.1.5. Cosmetics
12.4.2. Diagnostics
12.5. Market Value Forecast By End-user, 2017 – 2031
12.5.1. Health Care Providers
12.5.2. Pharmaceutical & Biotechnology Companies
12.5.3. Others
12.6. Market Value Forecast By Country, 2017 – 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Exosome Type
12.7.2. By Cell Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Exosome Technologies Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Exosome Type, 2017 – 2031
13.2.1. Loaded Cargos
13.2.1.1. Peptide
13.2.1.2. siRNA
13.2.1.3. mRNA
13.2.1.4. miRNA
13.2.1.5. Protein
13.2.1.6. Chemical
13.2.1.7. Others
13.2.2. Non-cargo
13.3. Market Value Forecast By Cell Source, 2017 – 2031
13.3.1. HEK293 Cells
13.3.2. MSCs
13.3.3. Platelets
13.3.4. Erythrocytes
13.3.5. Natural Killer Cells
13.3.6. Others
13.4. Market Value Forecast By Application, 2017 – 2031
13.4.1. Therapeutics
13.4.1.1. Oncology
13.4.1.2. Neurodegenerative Diseases
13.4.1.3. Cardiovascular Diseases
13.4.1.4. Infectious Diseases
13.4.1.5. Cosmetics
13.4.2. Diagnostics
13.5. Market Value Forecast By End-user, 2017 – 2031
13.5.1. Health Care Providers
13.5.2. Pharmaceutical & Biotechnology Companies
13.5.3. Others
13.6. Market Value Forecast By Country, 2017 – 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Exosome Type
13.7.2. By Cell Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country
14. Latin America Exosome Technologies Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Exosome Type, 2017 – 2031
14.2.1. Loaded Cargos
14.2.1.1. Peptide
14.2.1.2. siRNA
14.2.1.3. mRNA
14.2.1.4. miRNA
14.2.1.5. Protein
14.2.1.6. Chemical
14.2.1.7. Others
14.2.2. Non-cargo
14.3. Market Value Forecast By Cell Source, 2017 – 2031
14.3.1. HEK293 Cells
14.3.2. MSCs
14.3.3. Platelets
14.3.4. Erythrocytes
14.3.5. Natural Killer Cells
14.3.6. Others
14.4. Market Value Forecast By Application, 2017 – 2031
14.4.1. Therapeutics
14.4.1.1. Oncology
14.4.1.2. Neurodegenerative Diseases
14.4.1.3. Cardiovascular Diseases
14.4.1.4. Infectious Diseases
14.4.1.5. Cosmetics
14.4.2. Diagnostics
14.5. Market Value Forecast By End-user, 2017 – 2031
14.5.1. Health Care Providers
14.5.2. Pharmaceutical & Biotechnology Companies
14.5.3. Others
14.6. Market Value Forecast By Country, 2017 – 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Exosome Type
14.7.2. By Cell Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Exosome Technologies Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Exosome Type, 2017 – 2031
15.2.1. Loaded Cargos
15.2.1.1. Peptide
15.2.1.2. siRNA
15.2.1.3. mRNA
15.2.1.4. miRNA
15.2.1.5. Protein
15.2.1.6. Chemical
15.2.1.7. Others
15.2.2. Non-cargo
15.3. Market Value Forecast By Cell Source, 2017 – 2031
15.3.1. HEK293 Cells
15.3.2. MSCs
15.3.3. Platelets
15.3.4. Erythrocytes
15.3.5. Natural Killer Cells
15.3.6. Others
15.4. Market Value Forecast By Application, 2017 – 2031
15.4.1. Therapeutics
15.4.1.1. Oncology
15.4.1.2. Neurodegenerative Diseases
15.4.1.3. Cardiovascular Diseases
15.4.1.4. Infectious Diseases
15.4.1.5. Cosmetics
15.4.2. Diagnostics
15.5. Market Value Forecast By End-user, 2017 – 2031
15.5.1. Health Care Providers
15.5.2. Pharmaceutical & Biotechnology Companies
15.5.3. Others
15.6. Market Value Forecast By Country, 2017 – 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Exosome Type
15.7.2. By Cell Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. AEGLE Therapeutics
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Test Type Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Aruna Bio, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Test Type Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Bio-Techne Corporation (Exosome Diagnostics, Inc.)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Test Type Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Carmine Therapeutics, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Test Type Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Codiak BioSciences, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Test Type Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Creative Biolabs
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Test Type Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Danaher Corporation (Beckman Coulter, Inc.)
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Test Type Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Fujifilm Holdings Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Test Type Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. NOVADIP Biosciences S.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Test Type Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. OmniSpirant Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Test Type Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Thermo Fisher Scientific, Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Test Type Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview

List of Tables

Table 01: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 02: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 03: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 04: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 05: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 06: Global Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 07: Global Exosome Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 08: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 10: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 11: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 12: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 13: North America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 14: North America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 15: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 16: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 17: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 18: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 19: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 20: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 21: Europe Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 22: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 23: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 24: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 25: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 26: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 27: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 28: Asia Pacific Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 29: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 30: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 31: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 32: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 33: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 34: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 35: Latin America Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 36: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 37: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Exosome Type, 2017-2031

Table 38: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Loaded Cargos, 2017-2031

Table 39: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031

Table 40: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 41: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031

Table 42: Middle East & Africa Exosome Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031

★調査レポート[世界のエクソソーム技術市場2023-2031：エクソソーム種類別（ロードカーゴ（ペプチド、siRNA、mRNA、miRNA、タンパク質、化学物質、その他）、ノンカーゴ）] (コード：TMR23JUL201)販売に関する免責事項を必ずご確認ください。

★調査レポート[世界のエクソソーム技術市場2023-2031：エクソソーム種類別（ロードカーゴ（ペプチド、siRNA、mRNA、miRNA、タンパク質、化学物質、その他）、ノンカーゴ）]についてメールでお問い合わせ

MarketReport.jp

世界のエクソソーム技術市場2023-2031：エクソソーム種類別（ロードカーゴ（ペプチド、siRNA、mRNA、miRNA、タンパク質、化学物質、その他）、ノンカーゴ）

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料 総合販売サイト www.MarketReport.jp

市場調査レポート・産業資料総合販売サイト www.MarketReport.jp